Portfolio company
Replace Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops genome editing technology to insert and delete small DNA sequences for biotechnology firms and healthcare researchers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Seamless Therapeutics
The company develops programmable recombinase-based gene editing therapies for patients with severe genetic diseases through its proprietary technology platform.
Rewrite Therapeutics
This deep-tech company develops DNA writing and genome editing tools for biotechnology firms to treat genetic diseases.
Tessera
The company develops genome engineering platforms to write therapeutic DNA sequences into cells for clinicians and researchers treating genetic diseases.
Replay Therapeutics
This biotech company develops genome writing and delivery platforms to provide genetic medicines for patients with rare skin, eye and haematological diseases.
Salve Therapeutics
The company develops a bioengineering platform for designing and testing viral gene therapies to treat genetic disorders for biotechnology and pharmaceutical organisations.
Beam Therapeutics
The company develops precision genetic medicines using base editing technology to treat patients with serious genetic diseases such as sickle cell disease.
Stylus Medicine
This biotechnology company develops in vivo genetic medicines using engineered recombinases and lipid nanoparticles for patients with cancer, autoimmune and genetic diseases.
Epitome Therapeutics
This biotechnology firm develops an epigenome editing platform for programmable gene expression to treat patients with rare genetic and metabolic disorders.